Highly phosphorylated and sulfated recombinant factor ix
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorsFriedrich Scheiflinger, Ernst Boehm, Michele Himmelspach, Olaf Merkel
Life of this patent
Estimating the term…
Abstract
The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.
Claims7
1-11. (canceled)
A method of expressing recombinant blood coagulation human factor IX (rFIX), wherein at least 25% of the rFIX is fully phosphorylated and sulfated, the method comprising the step of expressing a nucleic acid encoding rFIX into an HEK 293 host cell type, said host cell comprising proteins with the ability to perform phosphorylation and sulfation as posttranslational modifications;
- thereby producing rFIX that is at least 25% fully phosphorylated and sulfated.
Dependencies are inferred from the claim text.